Founders keep asking me the same question before a Series A: "what number do I need to hit." The honest answer is that the number has always mattered less than what is behind it, and in 2026 that gap has widened further than at any point since the 2021 peak.

Carta's healthtech Series A benchmarking data tracks median deal size, valuation and dilution across the sector, and the trend across 2025 and into 2026 is toward larger rounds going to fewer companies, consistent with the broader market concentration Rock Health documented in H1 2026. That means the median headline masks a bimodal reality: a shrinking cohort of companies with real commercial traction raising comfortably, and a larger cohort of companies with a compelling story and no signed contract getting flatly passed on.

What "traction" means to a Series A investor in 2026, specifically

I have reviewed enough decks this cycle to see the pattern converge across investors who otherwise disagree on almost everything else. They are looking for:

  1. A signed, paying enterprise or payer contract, not a pilot MOU. Pilots that never convert to paid are treated as a negative signal now, not a neutral one.
  2. Evidence the contract will renew, meaning usage data inside the deployed customer, not just the signature.
  3. A repeatable sales motion, meaning the second and third contracts look structurally like the first one, not like bespoke one-off deals negotiated by the founder personally.
  4. A defensible reason the incumbent EHR, payer or health system cannot build this internally within 18 months. Analysis of the 2025-2026 European healthtech Series A environment describes this shift explicitly as a move away from "venture subsidised experimentation" toward what the piece calls disciplined maturity.

The metrics that actually move a term sheet

Net revenue retention above 100 percent inside your existing accounts is now treated as more predictive of Series B success than the size of the logo you just signed. A large hospital system contract with flat or declining usage a year in is a warning sign, not a trophy.

Gross margin discipline matters earlier than it used to. Services-heavy digital health businesses, where a large share of delivery still runs through human clinicians or care coordinators, are being priced differently than software-margin businesses even at identical ARR, because investors have watched services-heavy models struggle to scale profitably through the last cycle.

Time to first value for a new customer has become a diligence question in its own right. A shorter, evidenced implementation timeline reduces the perceived execution risk in your growth plan far more than an extra slide of TAM math.

What tier 1 healthcare investors are actually buying at Series A

One tier 1 healthcare VC breakdown of ground-level Series A activity makes a point worth repeating to every founder building a deck right now: investors at this stage are not buying a market thesis, they already have one. They are buying the specific, evidenced reason your company will be the one that captures it, backed by a contract, a cohort of renewing customers, or a regulatory position a competitor cannot quickly replicate.

A practical pre-raise checklist

  • Do you have at least one signed contract with usage data past the initial onboarding period, not just a signature.
  • Can you show net revenue retention, or expansion within an account, without hand-waving.
  • Is your gross margin trajectory believable at 3x your current scale, given your actual delivery model.
  • Does your investor dashboard already exist and update monthly, before diligence asks for it. High Rock's Series A investor dashboard breakdown is a useful reference for what a diligence team expects to see on day one, not week six.
  • Can you name, specifically, why a payer, EHR vendor or health system incumbent has not already built this.

The honest read

The Series A bar in healthtech has not gotten unreasonable. It has gotten literal. Investors are asking for evidence of the exact claims founders have always made in decks, they are simply no longer willing to fund the claim without the evidence attached. That is a harder market for a good story and a better market for a company that has already proven the thing it is asking capital to scale.